Congestive Heart Failure
Pipeline by Development Stage
Drug Modality Breakdown
Cardiovascular is a $69.4B mature market dominated by anticoagulants and metabolic therapies with stable blockbuster portfolios.
Key Trends
- FXa inhibitors (ELIQUIS, XARELTO) command 62% of market spending, creating limited room for new entrants
- SGLT2 inhibitors gaining traction in heart failure indication, signaling expansion beyond traditional anticoagulation
- Multiple patent cliffs (JANUVIA 2027, OPSUMIT 2029) create near-term revenue vulnerability but reinvestment pressure
Career Verdict
Strong choice for commercial, clinical operations, and device integration roles; limited opportunity for innovative pipeline development given market maturity.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | ELIQUIS (Apixaban) | Bristol Myers Squibb | $18.3B | 26% | Peak | Stable | 15.0yr |
| 2 | JARDIANCE (Empagliflozin) | Boehringer Ingelheim | $8.8B | 13% | Peak | Growing | 8.6yr |
| 3 | XARELTO (Rivaroxaban) | Johnson & Johnson | $6.3B | 9% | Peak | Stable | |
| 4 | FARXIGA (Dapagliflozin) | AstraZeneca | $4.3B | 6% | Peak | Growing | 15.4yr |
| 5 | JANUVIA (Sitagliptin) | Merck & Co. | $4.1B | 6% | LOE_Approaching | Declining | 1.1yr |
Drug Class Breakdown
Mature, stable revenue base
Growing in heart failure and renal indications
Declining as LOE approaches 2027
Stable in heart failure management
Niche pulmonary hypertension market
Career Outlook
StableCardiovascular careers are stable but not expanding; the market is mature, dominated by blockbuster franchises with predictable commercial cycles and patent cliffs. Professionals entering this space should expect strong compensation (Commercial $210K avg, Medical Affairs $201K avg) but limited opportunity to drive breakthrough innovation. Device company roles offer better growth trajectories than pharma, particularly in remote monitoring, diagnostics, and patient engagement technologies.
Breaking In
Target device companies (Abbott, Medtronic) for growth potential; if joining pharma, focus on Commercial or Clinical Operations roles where hiring is active and compensation is competitive.
For Experienced Professionals
Leverage cardiovascular expertise to move into medical device strategy, digital health partnerships, or adjacent therapeutic areas; R&D opportunity is limited and may require lateral moves to access innovation-focused roles.
In-Demand Skills
Best For
Hiring Landscape
Cardiovascular hiring is concentrated in device companies (Abbott 337, Medtronic 317) rather than pharma, reflecting the therapeutic area's reliance on hardware solutions and patient management infrastructure. Pharma hiring (Johnson & Johnson 261, Bristol Myers Squibb 52) is heavily weighted toward Commercial (468 roles) and Clinical Operations (296 roles), with minimal R&D investment (14 roles). Medical device integration and remote patient monitoring expertise are increasingly valued as the market consolidates.
Top Hiring Companies
By Department
Device companies offer more growth opportunities; pharma roles are high-paying but oriented toward mature market execution rather than innovation.
On Market (3)
Approved therapies currently available
Competitive Landscape
45 companies ranked by most advanced pipeline stage
+15 more companies
Trial Timeline
Clinical trial activity over time
Showing 15 of 50 trials with date data
Clinical Trials (50)
Total enrollment: 14,223 patients across 50 trials
Sacubitril-valsartan Versus Usual Anti-hypertensives in LVAD
Tolvaptan For Worsening Outpatient Heart Failure: Role of Copeptin In Identifying Responders
Improvement of Patients With Chronic Heart Failure Using NT-proBNP
Effect of a New Formulation of Torasemide (Prolonged Release)on Myocardial Fibrosis in Patients With Heart Failure.
BOAT: Beta Blocker Uptitration With OptiVol After Cardiac Resynchronization Therapy (CRT)
TRIAGE-CRT Telemonitoring in Patients With CHF and Indication of CRT-D
COSMO Post Approval Registry: Corox OTW Steroid LV Lead Monitoring
Safety Trial of OPC-61815 Injection in Patients With Congestive Heart Failure Who Have Difficulty With or Are Incapable of Oral Intake
Efficacy and Safety Trial of OPC-61815 Injection Compared With Tolvaptan 15-mg Tablet in Patients With Congestive Heart Failure
MADIT ASIA Cardiac Resynchronization Trial
Peritoneal Dialysis in Congestive Heart Failure
A Study to Compare the Effects of Coreg CR and Coreg IR on Heart Function in Subjects With Stable Chronic Heart Failure
DILIPO (DILutIonal HyPOnatremia)
APAF: Assessment of Cardiac Resynchronization Therapy in Patients With Permanent Atrial Fibrillation
EVEREST: Efficacy of Vasopressin Antagonism in hEart failuRE: Outcome Study With Tolvaptan
Study to Evaluate the Safety of Twice Daily Oral Carvedilol
Clinical Study of the EASYTRAK 3 Spiral Fixation Coronary Venous Bipolar Pace/Sense Lead
Device Evaluation of Contak Renewal 2and Easytrak 2 - DECREASE-HF
Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure
Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure
Evaluation of a Diagnostic Feature in a Cardiac Resynchronization Therapy (CRT) Device
Interventricular Delay of Lumax HF-T for Heart Failure
Heart Failure and Peritoneal Ultrafiltration
A Clinical Study Assessing the Potential of Piboserod for the Treatment of Heart Failure
PROCLAIM: Effect of AC2592 Administered by Continuous Subcutaneous Infusion in Subjects With Advanced Chronic Congestive Heart Failure
Effects of MK7418 on Diuresis and Renal Function in Congestive Heart Failure Patients
Multicenter, Randomized, Double-Blind, Placebo Controlled, Efficacy Study on the Effects of Tolvaptan on Left Ventricular Dilatation in Congestive Heart Failure Patients
Study to Compare the Effects of Two Dosages of Tolvaptan in Congestive Heart Failure Patients
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction
AC6 Gene Transfer for CHF
Empowering Elders Through Technology
A Study to Learn How the Study Treatment BAY1753011 Moves Into, Through and Out of the Body, How it Works, How Safe it is, and How it Affects the Body When Given Once as Tablet in Male and Female Participants With Reduced Kidney Function Compared to Matched Participants With Normal Kidney Function
AB-1002 in Patients With Class III Heart Failure
Phase I Study of OPC-61815
A Study Investigating the Safety, Tolerability, and Pharmacokinetics of MTP-131 in Subjects With Congestive Heart Failure
Cardiac Resynchronization and Iodine Meta-Iodobenzylguanidine (MIBG) Imaging
AutoLogous Human CArdiac-Derived Stem Cell to Treat Ischemic cArdiomyopathy (ALCADIA)
Baroreflex Activation Therapy in Left Ventricular Assist Device Patients Study
Verifying Remote Monitoring Effect on Net Cardiovascular Outcome; RemoteVerify (RêVe)
Study for the Evaluation of a Non-invasive Hemodynamic Measurement in Heart Failure Patients
Evaluating Efficacy of Digital Health Technology in the Treatment of Congestive Heart Failure
SyncAV Post-Market Trial
Comparing PA Compliance During and After Decompensation in HFP
Team-based Versus Primary Care Clinician-led Advance Care Planning in Practice-based Research Networks
Clinical Pharmacology Trial to Investigate the Dose of OPC-61815 Injection Equivalent to Tolvaptan 15-mg Tablet in Patients With Congestive Heart Failure
Paced And Sensed Electrical Delay in CRT Therapy (PASED CRT)
His Bundle Pacing Versus Coronary Sinus Pacing for Cardiac Resynchronization Therapy
Cardiovascular Diagnosis Using µ-Cor - an Interventional Pilot Trial
Engaging Patients in Heart Failure Management
New Echocardiographic Parameters for Prediction of Response to Cardiac Resynchronization Therapy
Related Jobs in Cardiovascular
Director, Clinical Trial Liaison - Northern Midwest: Illinois; Indiana; Michigan; Minnesota; Missouri; Iowa; North Dakota
Director, Clinical Trial Liaison - Mid Atlantic Region (NJ, NY, PA, MA, MD)
Director, Value-Based Partnerships – Point-of-Care Ultrasound
Medical Director, US Rare Cardiac, MD
Medical Director, US Rare Cardiac, non-MD
Supervisor of Product Technical Support
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.